Plus Therapeutics (NASDAQ:PSTV – Get Free Report) posted its earnings results on Wednesday. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $0.34, RTT News reports. The company had revenue of $1.68 million for the quarter. Plus Therapeutics had a negative return on equity of 805.57% and a negative net margin of 271.04%. During the same quarter last year, the firm earned ($2.10) EPS.
Plus Therapeutics Stock Down 2.6 %
Shares of NASDAQ PSTV traded down $0.06 during trading hours on Thursday, hitting $2.26. 10,880 shares of the stock were exchanged, compared to its average volume of 57,460. Plus Therapeutics has a 12 month low of $0.97 and a 12 month high of $4.45. The firm has a fifty day moving average price of $1.84 and a 200-day moving average price of $1.88. The company has a market cap of $9.67 million, a PE ratio of -0.07 and a beta of 0.55.
Insider Activity at Plus Therapeutics
In other Plus Therapeutics news, CEO Marc H. Hedrick bought 12,255 shares of the company’s stock in a transaction that occurred on Wednesday, May 8th. The shares were purchased at an average cost of $2.04 per share, for a total transaction of $25,000.20. Following the purchase, the chief executive officer now directly owns 12,425 shares in the company, valued at $25,347. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders bought 26,961 shares of company stock valued at $55,000 over the last 90 days. Insiders own 2.32% of the company’s stock.
About Plus Therapeutics
Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Further Reading
- Five stocks we like better than Plus Therapeutics
- What is Insider Trading? What You Can Learn from Insider Trading
- Cisco Systems Rebound is On: Double-Digit Upside to Come
- Roth IRA Calculator: Calculate Your Potential Returns
- This Walmart Rally has Legs: 20% Upside Left To Go
- The Role Economic Reports Play in a Successful Investment Strategy
- 5 Companies Leading the Charge With Robotic Solutions
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
